Company Profile
Idorsia Ltd, a biopharmaceutical company provides the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.
The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease.
Its portfolio also includes Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia, IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis, ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo, and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis.
It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders. Its portfolio also includes IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders, and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan.
Its portfolio also includes collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products, and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Incorporated in 2017, Idorsia is headquartered in Allschwil, Switzerland.